{
    "id": 3522,
    "fullName": "FGFR3 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2261,
        "geneSymbol": "FGFR3",
        "terms": [
            "FGFR3",
            "ACH",
            "CD333",
            "CEK2",
            "HSFGFR3EX",
            "JTK4"
        ]
    },
    "variant": "amp",
    "createDate": "03/05/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10012,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 3996,
                "name": "urinary system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10026,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 3996,
                "name": "urinary system cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7899,
                    "pubMedId": 27401245,
                    "title": "c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27401245"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2480,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3158,
                    "pubMedId": null,
                    "title": "Abstract 3560: Ponatinib (AP24534), a potent pan-FGFR inhibitor with activity in multiple FGFR-driven cancer models",
                    "url": "http://cancerres.aacrjournals.org/content/71/8_Supplement/3560.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17088,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15194,
                    "pubMedId": 30745300,
                    "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30745300"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2482,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2252,
                    "pubMedId": null,
                    "title": "Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/CT326.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8411,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 3583,
                "therapyName": "PRN1371",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10753,
                    "pubMedId": 28978721,
                    "title": "The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28978721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14162,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MATCH) trial, AZD4547 treatment resulted in stable disease in 59% (10/17) of patients with advanced solid tumors harboring FGFR amplification, with a 6-month progression-free survival rate of 15% (J Clin Oncol 36, 2018 (suppl; abstr 2503); NCT02465060).",
            "molecularProfile": {
                "id": 3329,
                "profileName": "FGFR3 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11482,
                    "pubMedId": null,
                    "title": "Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.",
                    "url": "https://meetinglibrary.asco.org/record/161579/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12617,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Votrient (pazopanib) treatment resulted in a partial response that lasted more than 6 months in a patient with bladder papillary urothelial carcinoma harboring FGFR3 S249C, and amplification of FGFR3, FGF19, and CCND1 (PMID: 25766722).",
            "molecularProfile": {
                "id": 28792,
                "profileName": "CCND1 amp FGF19 amp FGFR3 S249C FGFR3 amp"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 5432,
                "name": "bladder papillary transitional cell neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10498,
                    "pubMedId": 25766722,
                    "title": "Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25766722"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14609,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).",
            "molecularProfile": {
                "id": 30338,
                "profileName": "ROS1 fusion ERBB2 amp FGFR3 amp RET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3329,
            "profileName": "FGFR3 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7558,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR3 amp"
                },
                {
                    "id": 7560,
                    "name": "FGFR3 Inhibitor",
                    "profileName": "FGFR3 amp"
                },
                {
                    "id": 7559,
                    "name": "FGFR3 Antibody",
                    "profileName": "FGFR3 amp"
                }
            ]
        },
        {
            "id": 28792,
            "profileName": "CCND1 amp FGF19 amp FGFR3 S249C FGFR3 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30338,
            "profileName": "ROS1 fusion ERBB2 amp FGFR3 amp RET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}